Canada markets closed

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.90+0.21 (+1.53%)
At close: 4:00PM EDT
Sign in to post a message.
  • F
    Fissber
    Getting ready for the bounce back up. Buy rating: 6.5, according to 9trading http://www.foxchart.com/share/989839487SNDX.png
  • Y
    Yahoo Finance Insights
    Syndax Pharmaceuticals is down 8.15% to 14.32
  • M
    Mike
    I sold all my stocks yesterday, various prices, mostly above 13.00. I will wait until April to buy it again.
  • M
    Mike
    heading back below 11.00
  • M
    Mike
    60 more patients that means 6 more months to wait for phase 3 trial. best case senario.
  • C
    Chari
    What is going on with the his stock? Is this affected by Merck's keytruda trial data?
  • c
    carlx
    5 Directors added 10,000 shares apiece recently. Good news in the future you think?
  • M
    Mike
    SNDX presentation at Cowen got the CAT out of the box. Phase 3 Breast Cancer, soon Melanoma go to Phase 3. CRC and NSCLC data of Phase 2 is out.
  • T
    T-Rex
    WOW! Someone thinks that SNDX (currently trading at 5.44) is worth $6, then $12, then $18: (sounds like quite a buy at current prices!!):

    ("Syndax" or the "Company") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other leading life sciences investors for the purchase of 4,366,666 shares of common stock at a purchase price of $6.00 per share, representing a premium of 30% to the share price as of market close on Tuesday, March 26, as well as warrants to purchase up to 2,183,331 shares of common stock at an exercise price of $12.00 per share, and warrants to purchase up to 2,183,335 shares of common stock at an exercise price of $18.00 per share.

    Syndax anticipates aggregate gross proceeds from the offering will be approximately $26.2 million (excluding any proceeds to be received upon exercise of the warrants). Closing of the transaction is expected to occur on or about March 29, 2019.
  • J
    James Dean
    I see that Syndax shares have added about 105.4% since the beginning of the year versus the S&P 500's gain of 15%. This is good news considering the company's quarterly loss of .47 per share. The good news being that a year ago they reported a loss of .74 a share. The company is cash rich and ready to go the distance in the process with the FDA. I'd say this is a hold. Thoughts?

    (Disclaimer: I am not an institutional or professional investor and I am long on this stock).
  • v
    vting
    Hi, anyone knows any upcoming news or business event for Sdnx?
  • M
    Mike
    sell, it will tank by the end of the day
  • B
    Barbara Ann
    $15-16 close?
  • C
    Captainodestin
    Bad news leaking out?
  • M
    MD
    Results seem ok, why the drop?
  • B
    BakoBob
    Shorts are winning here.
  • B
    Bernardo
    Just bought in at 8. Stock is down significantly in 2 days on no news. Does anyone know why?
  • C
    Cash
    What is going on? Has to be news somewhere, but I see nothing.
  • M
    Mike
    melanoma phase 3 soon. CRC data in May.
  • A
    Agamemnus
    These results are only 1% less (on ORR) than in May. May had 11% ORR with 57 patients, now it's at 10% with 72. That's when the price went from $11.12 to $8.6.

    And now the price is in low $6s.